These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9396618)

  • 61. Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines.
    Walther MM; Trahan EE; Cooper M; Venzon D; Linehan WM
    J Urol; 1994 Nov; 152(5 Pt 1):1599-602. PubMed ID: 7933214
    [TBL] [Abstract][Full Text] [Related]  

  • 62. New sulfonated distamycin A derivatives with bFGF complexing activity.
    Ciomei M; Pastori W; Mariani M; Sola F; Grandi M; Mongelli N
    Biochem Pharmacol; 1994 Jan; 47(2):295-302. PubMed ID: 7508230
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of suramin on human esophageal cancer cells in vitro and in vivo.
    Shin R; Naomoto Y; Kamikawa Y; Tanaka N; Orita K
    Scand J Gastroenterol; 1997 Aug; 32(8):824-8. PubMed ID: 9282976
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Antiproliferative effects of suramin on androgen responsive tumour cells.
    Berns EM; Schuurmans AL; Bolt J; Lamb DJ; Foekens JA; Mulder E
    Eur J Cancer; 1990 Apr; 26(4):470-4. PubMed ID: 2141513
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Suramin inhibits growth and transforming growth factor-beta 1 (TGF-beta 1) binding in osteosarcoma cell lines.
    Kloen P; Jennings CL; Gebhardt MC; Springfield DS; Mankin HJ
    Eur J Cancer; 1994; 30A(5):678-82. PubMed ID: 8080687
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer.
    Kalli KR; Bradley SV; Fuchshuber S; Conover CA
    Gynecol Oncol; 2004 Sep; 94(3):705-12. PubMed ID: 15350362
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Stimulation of tumor growth in vitro and in vivo by suramin on the VX2 model.
    Ramirez LH; Juliéron M; Bonnay M; Koscielny S; Zhao Z; Gouyette A; Munck JN
    Invest New Drugs; 1995; 13(1):51-3. PubMed ID: 7499108
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells.
    Funayama Y; Nishio K; Takeda Y; Kubota N; Ohira T; Ohmori T; Ohta S; Ogasawara H; Hasegawa S; Saijo N
    Anticancer Res; 1993; 13(6A):1981-8. PubMed ID: 8297104
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines.
    Shiao RT; Miglietta L; Khera SY; Wolfson A; Freter CE
    Leuk Lymphoma; 1995 May; 17(5-6):485-94. PubMed ID: 7549842
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action.
    Bojanowski K; Nishio K; Fukuda M; Larsen AK; Saijo N
    Biochem Biophys Res Commun; 1994 Sep; 203(3):1574-80. PubMed ID: 7945307
    [TBL] [Abstract][Full Text] [Related]  

  • 71. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
    Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
    Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor.
    Maekawa R; Maki H; Yoshida H; Hojo K; Tanaka H; Wada T; Uchida N; Takeda Y; Kasai H; Okamoto H; Tsuzuki H; Kambayashi Y; Watanabe F; Kawada K; Toda K; Ohtani M; Sugita K; Yoshioka T
    Cancer Res; 1999 Mar; 59(6):1231-5. PubMed ID: 10096553
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties.
    Maragoudakis ME; Missirlis E; Karakiulakis GD; Sarmonica M; Bastakis M; Tsopanoglou N
    Kidney Int; 1993 Jan; 43(1):147-50. PubMed ID: 7679456
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures.
    Gansler T; Vaghmar N; Olson JJ; Graham SD
    J Urol; 1992 Sep; 148(3):910-4. PubMed ID: 1512858
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine.
    Arrieta O; Guevara P; Reyes S; Ortiz A; Rembao D; Sotelo J
    Eur J Cancer; 1998 Dec; 34(13):2101-6. PubMed ID: 10070318
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of suramin on the mitogenic response of the human prostate carcinoma cell line PC-3.
    Ewing MW; Liu SC; Gnarra JR; Walther MM; Meyers CE; Linehan WM
    Cancer; 1993 Feb; 71(3 Suppl):1151-8. PubMed ID: 8428338
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antiproliferative effects of suramin on lymphoid cells.
    Spigelman Z; Dowers A; Kennedy S; DiSorbo D; O'Brien M; Barr R; McCaffrey R
    Cancer Res; 1987 Sep; 47(17):4694-8. PubMed ID: 3621163
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Surface-enhanced Raman scattering and DFT investigation of Eriochrome Black T metal chelating compound.
    Szabó L; Herman K; Leopold N; Buzumurgă C; Chiş V
    Spectrochim Acta A Mol Biomol Spectrosc; 2011 Jun; 79(1):226-31. PubMed ID: 21420900
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mechanisms of growth stimulation by suramin in non-small-cell lung cancer cell lines.
    Lokshin A; Peng X; Campbell PG; Barsouk A; Levitt ML
    Cancer Chemother Pharmacol; 1999; 43(4):341-7. PubMed ID: 10071987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.